Glycemia is strongly associated with β-cell dysfunction in adults with early T2DM treated with metformin alone. Efforts to improve glycemia should focus on interventions aimed at improving β-cell function (Journal of Diabetes and Its Complications)
Diabetes News
Glycosmedia is dedicated to bringing free, non-promotional, editorially independent news to a global audience about developments in diabetes, and is primarily aimed at health professionals.
Early markers of periodontal disease and altered oral microbiota are associated with glycemic control in children with type 1 diabetes
Children with type 1 diabetes showed a continuous relationship between less favorable glycemic control and increased early markers of periodontal disease. Glycemic control was also related to the complexity and richness of the plaque microbiota, with diversity increasing as HbA1c levels increase (Pediatric Diabetes)
Pedobarographic Statistical Parametric Mapping may identify specific plantar pressure patterns in patients with diabetes mellitus among different degrees of peripheral neuropathy: a pilot study
pSPM may identify specific features of plantar pressure distribution during walking in patients with mild PN and may become a useful screening tool for a timely identification of this complication (Diabetic Medicine)
Intrahepatic cholestasis of pregnancy: association with glycaemic control in gestational diabetes
Under the current treatment guidelines, ICP is not associated with clinically significant changes in glycaemic control in GDM. Significantly more women with both GDM and ICP developed preeclampsia (Diabetic Medicine)
The association between hypoglycemia and glycemic variability in elderly patients with type 2 diabetes: a prospective observational study
Among elderly patients with type 2 diabetes, CV reflected TBR ≥ 1% most appropriately among the GV indices examined (Diabetology & Metabolic Syndrome)
Abnormal N-Glycosylation of Human Lens Epithelial Cells in Type-2 Diabetes May Contribute to Cataract Progression
These results suggest that over-expression of N-glycosidically linked human type 1 cytokeratin may induce capsule disruption and affect selective permeability, allowing the entry of different molecules to the lens that facilitate cataract progression (Clinical Ophthalmology)
Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England
In the context of the COVID-19 pandemic, there is no clear indication to change prescribing of glucose-lowering drugs in people with type 2 diabetes (Lancet)
Type 1 diabetes in adults: diagnosis and management (update)
In development [GID-NG10159] Expected publication date: 21 July 2021. A list of downloadable documents created during development (NICE)
Insulin Metrics: Need for Development of Consensus Standards for Reporting of Insulin Dosing Data
There is an urgent need for the diabetes community to work toward developing a consensus regarding the most effective methods to characterize and report insulin dosing data and to integrate insulin and glucose data reports (Diabetes Technology & Therapeutics)
Effect of sodium–glucose co-transporter-2 inhibitors on the levels of serum asprosin in patients with newly diagnosed type 2 diabetes mellitus
These findings indicated that SGLT2 inhibitors can lower serum asprosin levels and improve glucolipid and weight in patients with newly diagnosed T2DM, which may benefit the cardiovascular system (Diabetology & Metabolic Syndrome)
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
Among adults with overweight or obesity who completed a 20-week run-in period with subcutaneous semaglutide, 2.4 mg once weekly, maintaining treatment with semaglutide compared with switching to placebo resulted in continued weight loss over the following 48 weeks (JAMA)
Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
This observational study suggests that treatment with GLP-1RA and SGLT-2i result in very similar cardiorenal outcomes. In the short term, treatment with GLP-1RA seem to be associated with lower risks of stroke and peripheral artery disease, whereas SGLT-2i seem to be nominally associated with lower risk of heart failure and total mortality (Cardiovascular Diabetology)
Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1)
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial (Diabetes Care)
Metformin and health outcomes: An umbrella review of systematic reviews with meta‐analyses
Observational evidence on metformin seems largely unreliable. Randomized evidence shows benefits for preventing diabetes and in some gynaecological and obstetrical settings. However, almost all meta‐analyses are of low or critically low quality according to AMSTAR 2 criteria (European Journal of Clinical Investigation)
The All‐Wales Medicines Strategy Group: 18 years’ experience of a National Medicines Optimisation Committee
Since 2002, AWMSG has acted as a national medicines optimisation committee in Wales. From the outset, pharmacists and clinical pharmacologists have collaborated closely and shared their complementary expertise to make a much greater contribution to the safe, effective, and cost‐effective use of medicines than either group could have achieved by working separately (British Journal of Clinical Pharmacology)
Increased frequency of β cells with abnormal NKX6.1 expression in type 2 diabetes but not in subjects with higher risk for type 2 diabetes
Our results suggested that NKX6.1 expression in β cells was changed in type 2 diabetic subjects, evidenced by significantly increased NKX6.1Nuc-Ins+ and NKX6.1cytIns− cells. This abnormality did not occur more frequently in subjects with a higher risk for T2DM, suggesting that β cell dedifferentiation might be secondary to the pathological changes in T2DM (BMC Endocrine Disorders)
Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes
Given the absence of approved therapies for NAFLD-fibrosis, it would be reasonable to initiate specific randomized controlled trials with statins (Metabolism – Clinical and Experimental)
Approvals of type 2 diabetes drugs tested in cardiovascular outcome trials: a tripartite comparison
Regulatory authorities using identical trial data made substantially different decisions regarding both safety and efficacy of hypoglycemic drugs. The differences in initial indication wording between Japan and the other authorities suggest that trial data and T2D are interpreted differently in these regions (British Journal of Clinical Pharmacology)
Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes
Compared with Whites, Asians may derive greater CV death/HHF benefit from SGLT2is in patients with HFrEF, and MACE benefit from GLP-1RAs in patients with type 2 diabetes (Diabetes Care)
Low‐density lipoprotein cholesterol and lifespan: a Mendelian randomization study
This genetic evidence supports that higher LDL‐c levels reduce lifespan and longevity. In a general population that is not selected for increased cardiovascular risk, there is likely a net lifespan benefit of LDL‐c lowering therapies, particularly for PCSK9 inhibitors, although randomized controlled trials are necessary before modification of clinical practice (British Journal of Clinical Pharmacology)
Glycosmedia is also available as an App: